Amicus Therapeutics Inc Q4 2023 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Malcolm Kuno - JPMorgan Chase & Co - Analyst : Hi, thank you for taking the question. This is actually now Malcolm Kuno on for Anupam. So, in the US with regard to pump pay, are you seeing switches from patients that are clearly progressing or patients who are stable, but just not gaining a benefit from their current treatment?

Question: Malcolm Kuno - JPMorgan Chase & Co - Analyst : Great. Thanks, Brett.

Question: Ritu Baral - TD Cowen - Analyst : Good morning, guys. Thanks for taking the question and to drill down a little further on that, Brad and Sebastian, following you guys seeing clinicians in the field define the decliners and the two symposiums that world, both yours and your competitors having spent a lot of time on defining decliners defining stable. What do you see in your conversations during the conference on the tools that clinicians are using to define that in their own head? Have you done any market research on segmentation of the population into sort of that definition of decliner, that definition of stable as you see it now?

Question: Ritu Baral - TD Cowen - Analyst : Great. Thanks.

Question: Dae Gon Ha - Stifel, Nicolaus & Company - Analyst : Good morning, guys. Thanks for taking our question on pump pay, if you can just remind us on the 15 that were new and not part of the expanded access or clinical trial, did you guys ever break them down in terms of geographies? And I guess what I'm thinking about is 2024, how we should think about the cadence of patient onboarding, given that you have these multiple launches going on? Thanks so much.

Question: Dae Gon Ha - Stifel, Nicolaus & Company - Analyst : But any visibility on ex-US versus US kind of the cadence of growth that you anticipate this year? without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies. FEBRUARY 28, 2024 / 1:30PM, FOLD.OQ - Q4 2023 Amicus Therapeutics Inc Earnings Call

Question: Dae Gon Ha - Stifel, Nicolaus & Company - Analyst : Excellent. Thank you very much.

Question: Joseph Schwartz - Leerink Partners LLC - Analyst : Thanks so much, and congrats on the progress of. It's interesting that you're getting more switches from Nexviazyme and Lumizyme. So I was wondering if you could talk about why that might be? Maybe give us some color in terms of the proportion of each of those subsegments that you think might be deemed to not be improving and yes, just give us any color in terms of that dynamic, that would be helpful. Thank you.

Question: Joseph Schwartz - Leerink Partners LLC - Analyst : Great. Just to follow up, if I could. Does it indicate or could it indicate at all that some patients on that Nexviazyme patients are essentially self selecting them more severe and there might be more people on Lumizyme in the United States that are satisfied and they might be harder to switch.

Question: Joseph Schwartz - Leerink Partners LLC - Analyst : Very helpful. Thank you.

Question: Eliana Merle - UBS Investment Bank - Analyst : And congrats on the progress, and thanks for taking the question. Just if you could talk a little bit more income pay in terms of the numbers of centers or physicians that you're targeting as the key prescriber base here? And I guess what proportion of these have already written a script for possibility of full data like you mentioned that you're seeing increasing starts at an increasing rate. Are you seeing something similar in terms of the specific new physicians? Or is it a deepening of prescriptions from those sites that were already prescribing or involved in the clinical trials? Thanks.

Question: Eliana Merle - UBS Investment Bank - Analyst : And then just of the 120 patients that you mentioned at JPMorgan, I guess, any color on what proportion of these are already reimburse them?

Question: Eliana Merle - UBS Investment Bank - Analyst : Great. Thanks so much.

Question: Jeff Hung - Morgan Stanley - Analyst : Thanks for taking my question. I mean, you talked about the seasonal patterns you've seen in the past with Galafold going from Q4 to Q1. How should we think about the potential seasonal trends for probability and unfold. I know would you expect them to move similarly? Or do you think that maybe it doesn't apply as much this year given that the launch is still fairly early? Thanks.

Question: Jeff Hung - Morgan Stanley - Analyst : Thank you.

Question: Kristen Kluska - Cantor Fitzgerald & Co. - Analyst : Hi, good morning, everybody. The patient diagnosis growth has been really impressive. Fabric growing 70% from 2015 to 2023. So since part of this growth came from new therapies on the market, including your own. Curious how you're thinking about some of the growth we might see in the postpaid market numbers with the recent launches?

Question: Kristen Kluska - Cantor Fitzgerald & Co. - Analyst : Thank you.